Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App





Rockefeller Foundation Lays Out Massive COVID-19 Testing Action Plan for US

By LabMedica International staff writers
Posted on 22 Apr 2020
The Rockefeller Foundation (New York, NY, USA) has laid out a National COVID-19 Testing Action Plan which outlines the precise steps necessary to enact robust testing, tracing, and coordination to more safely reopen the US economy – starting with a dramatic expansion of testing from one million tests per week to initially three million per week and then 30 million per week. The effort will be backed by an Emergency Network for COVID-19 Testing to coordinate and underwrite the testing market, a public-private testing technology accelerator, and a national initiative to rapidly expand and optimize the use of US, university, and local lab capacity. The goal of the Action Plan is to build a state-led national program of COVID-19 testing that supports reopening the US economy through the goals of work-force monitoring, early detection of recurrent outbreaks, and diagnostic and home testing. This would be the largest public health testing pro-gram in American history and its success will depend on the active engagement of the government, business, philanthropy, and the public.

In the past two weeks, the Rockefeller Foundation has brought together experts and leaders from science, industry, academia, public policy, and government – across sectors and political ideologies – to create a clear, pragmatic, data-driven, actionable plan to beat back COVID-19 and get Americans back to work more safely. The Rockefeller Foundation believes that testing is the way out of this crisis, and instead of ricocheting between an unsustainable shutdown and a dangerous, uncertain return to normalcy, the US must mount a sustainable strategy with better tests and contact tracing, and stay the course for as long as it takes to develop a vaccine or cure.

The Rockefeller Foundation and its finance partners will help create an emergency procurement network, the Emergency Network for Covid-19 Testing, that can leverage public-private credit guarantees, define pooled procurement requirements for critical testing and supplies and negotiate medium term (3-6 month) contracts with suppliers to make sure large volumes of critical supplies are accessible to purchasing cooperatives, health systems, state and local governments, working alone or together, and other buyers. The aim of the ENCT would be to support and complement the work of federal and state agencies by engaging with producers of testing equipment, reagents, and other lab consumables; national, state and local purchasers; public and private healthcare funders; and financial institutions. The intent is to overcome market, government, logistical, and diagnostic industry challenges that have plagued the dramatic scale up in COVID-19 diagnostic testing required to reopen the US economy.

The Action Plan also includes launching a Covid Community Healthcare Corps so that every American can easily get tested with privacy-centric contact tracing; a testing data commons and digital platform to track COVID-19 statuses, resources, and effective treatment protocols across states and be a clearinghouse for data on new technologies; and a Pandemic Testing Board, in line with other recommendations, to bridge divides across governmental jurisdictions and professional fields.

Related Links:
The Rockefeller Foundation


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.